Share this article
WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group. In this role, Dr. Woodman will have full oversight and responsibility for the strategic and operational leadership of the company s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He will also serve as a member of the Oncology Executive Leadership team.
Dr. Richard Woodman
Dr. Woodman, who has 18 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, will lead the clinical team s development of Eisai s next generation oncology products by managing the design protocols and implementation of all oncology clinical trials. He w
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary